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Abstract
Epithelial ovarian cancer (EOC) is thought to arise in part from the ovarian surface epithelium (OSE); however, the molecular
events underlying this transformation are poorly understood. Germline mutations in the BRCA1 tumor suppressor gene
result in a significantly increased risk of developing EOC and a large proportion of sporadic EOCs display some sort of BRCA1
dysfunction. To generate a model in which Brca1-mediated transformation can be studied, we previously inactivated Brca1
alone in murine OSE, which resulted in an increased accumulation of premalignant changes, but no tumor formation. In this
study, we examined tumor formation in mice with conditionally expressed alleles of Brca1, p53 and Rb, alone or in
combination. Intrabursal injection of adenovirus expressing Cre recombinase to inactivate p53 resulted in tumors in 100% of
mice. Tumor progression was accelerated in mice with concomitant inactivation of Brca1 and p53, but not Rb and p53.
Immunohistologic analyses classified the tumors as leiomyosarcomas that may be arising from the ovarian bursa. Brca1
inactivation in primary cultures of murine OSE cells led to a suppression of proliferation that could be rescued by
concomitant inactivation of p53 and/or Rb. Brca1-deficient OSE cells displayed an increased sensitivity to the DNA damaging
agent cisplatin, and this effect could be modulated by inactivation of p53 and/or Rb. These results indicate that Brca1
deficiency can accelerate tumor development and alter the sensitivity of OSE cells to chemotherapeutic agents. Intrabursal
delivery of adenovirus intended to alter gene expression in the ovarian surface epithelium may, in some strains of mice,
result in more rapid transformation of adjacent cells, resulting in leiomyosarcomas.
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Introduction
Epithelial ovarian cancer (EOC) is thought to arise from the
ovarian surface epithelium (OSE) [1], although recent evidence
implicates the fallopian tube as a potential tissue of origin of EOC of
the serous histotype [2–5]. Embryonically derived from the coelemic
epithelium, the OSE is a single layer of squamous to cuboidal cells
that demonstrates a plastic phenotype reflecting its ability to undergo
epithelio-mesenchymal transition [6]. With age and repeated
ovulatory cycles, the OSE assumes a more irregular contour and
forms invaginations or clefts into the stroma, which may pinch off
completely and form epithelial inclusion cysts within the ovary. These
crypts and cysts often show evidence of early metaplastic changes in
cell shape and express markers up-regulated in ovarian tumors, such
as E-cadherin [7] and CA125 [1], which suggests that these
premalignant lesions may give riseto ovarian neoplasias. Prophylactic
oophorectomy specimens from women at high risk for developing
ovarian cancer, due to a strong family history of the disease or the
presence of a germline mutation in BRCA1,h a v em o r eo ft h e s e
morphological changes in the OSEthan ovaries removed incidentally
during total abdominal hysterectomy [8–10]. In one study, 6% of
prophylactically removed ovaries from BRCA1 mutation carriers
were found to harbor microscopic ovarian carcinomas [11].
Five to fifteen percent of ovarian cancers are thought to be due
to hereditary factors and the majority of these can be attributed to
germline mutations in the BRCA1 gene [12,13]. These germline
mutations confer a lifetime risk of ovarian cancer up to 60%
compared to ,2% in the general population [14,15]. Although
somatic mutations in BRCA1 are rare, reduced or absent protein
expression has been observed in up to 90% of sporadic ovarian
tumors indicating that epigenetic factors, mainly promoter
hypermethylation, are also involved in its regulation [16–18].
The BRCA1 gene has been implicated in a wide variety of cellular
processes, including maintenance of genome integrity [19], DNA
damage recognition and repair [20,21], cell cycle checkpoint
control [22,23], and apoptosis [24].
Up to 60% of BRCA1 mutation-associated ovarian tumors also
display mutations in the p53 tumor suppressor gene [25,26].
Mouse models of mammary tumorigenesis have revealed a role for
p53 in Brca1-related transformation [27–29]. In mice in which
Brca1 was inactivated in the mammary epithelium, the latency of
tumor formation could be shortened by the concomitant
inactivation of the p53 tumor suppressor gene [30,31]. Down-
regulaton of BRCA1 results in increased p53 and p21 expression
[31], which may represent a significant obstacle to tumorigenesis
that can be overcome by somatic mutation of the p53 gene.
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8534The ability of BRCA1 to suppress cellular proliferation may
depend, at least in part, on its association with the retinoblastoma
tumor suppressor (RB), since RB preferentially binds to exon 11 of
BRCA1 [32]. RB has also been shown to modify BRCA1 expression
via its modulation of E2F transcriptional activity, with BRCA1
being an in vivo target of E2F1 [33]. And overexpression of BRCA1
inhibits the expression of RB and the RB family members p107 and
p130 [34]. No association has yet been made between RB and
BRCA1 dysfunction in ovarian cancer.
The Brca1, Rb and p53 tumor suppressors have been
conditionally inactivated in mouse OSE to study their roles in
ovarian epithelial cell transformation. Simultaneous inactivation of
p53 and Rb in the mouse OSE led to the development of malignant
ovarian tumors [35]. We inactivated Brca1 in the murine OSE
which resulted in the increased accumulation of premalignant
changes, although no tumor formation was observed after one
year [36]. However, inactivation of Brca1 in cultured murine OSE
(MOSE) cells resulted in a slowed proliferation that could be
rescued by concurrent inactivation of p53 [36]. In the present
study, a conditional and site-directed strategy was employed to test
whether inactivation of Brca1, p53, and Rb in various combinations
in the OSE is sufficient to establish a mouse model of Brca1-
associated ovarian cancer. The ovaries of these mice were
examined at various time points to determine if there were
progressive alterations in epithelial morphology or tumor forma-
tion as has been observed in human prophylactic oophorectomy
specimens. Primary cultures of OSE cells from these mice were
also established to determine the impact of combined inactivation
of these genes on their rate of proliferation and sensitivity to
cisplatin.
Materials and Methods
Experimental Animals
Brca1
loxP/loxP [FVB;129-Brca1
tm2Brn] conditional knockout mice,
bearing loxP sites in introns 4 and 13 of the Brca1 gene, and
p53
loxP/loxP [FVB;129-Trp53
tm1Brn] [37] mice bearing loxP in
introns 1 and 10 of the p53 gene were obtained from the Mouse
Models of Human Cancers Consortium Mouse Repository
(National Cancer Institute, Rockville, MD, USA). Rb
loxP/loxP mice
[129sv-Rb1
tm2Brn] [38], bearingloxP sites flanking exon 19 of the Rb
gene, were obtained from Dr. Ruth Slack at the University of
Ottawa (Ottawa, Ontario, Canada). The mice were intercrossed
through multiple generations to create colonies of homozygous
Brca1
loxP/loxP/p53
loxP/loxP, Rb
loxP/loxP/p53
loxP/loxP, and Rb
loxP/loxP/
Brca1
loxP/loxP double conditional knockout mice. These mice were
then intercrossed through successive generations in order to obtain
Brca1
loxP/loxP/Rb
loxP/loxP/p53
loxP/loxP triple conditional knockout
mice. All animal experiments described in this study were
performed according to the Guidelines for the Care and Use of Animals
established by the Canadian Council on Animal Care. Recombi-
nant adenoviruses Ad5CMVeGFP (AdGFP) or Ad5CMVCre
(AdCre) (Vector Development Laboratory, Houston, TX) were
delivered to the OSE in vivo via intrabursal injection as previously
described [36].
Genotyping and Detection of Recombination
Genomic DNA was extracted from ear punches or cultured cells
as previously described [36]. Brca1
loxP/loxP mice were genotyped as
previously described [39]. p53
loxP/loxP mice were genotyped using
primers p53int1fwd (59 CAC AAA AAC AGG TTA AAC CAG
39) and p53int1rev (59 AGC ACA TAG GAG GCA GAG AC 39)
to yield a 288 bp band for wild-type or a 370 bp band for floxed
sequences or primers p53int10fwd (59 AAG GGG TAT GAG
GGA CAA GG 39) and p53int10rev (59 GAA GAC AGA AAA
GGG GAG GG 39), which yield a 431 bp or a 584 bp fragment
for wild-type and floxed sequences respectively. For detection of
Cre-mediated excision of exons 2–10 of p53 (hereafter designated
p53
D2-10), primers p53int1fwd and p53int10rev were used, yielding
a 612 bp product. Remaining unrecombined sequence following
Cre exposure was detected using primers p53int1fwd and
p53int1rev or primers p53int10fwd and p53int10rev in a separate
amplification. Rb
loxP/loxP mice were genotyped using primers
Rb18 (59 GGC GTG TGC CAT CAA TG 39) and Rb19 (59 AAC
TCA AGG GAG ACC TG 39). DNA from wild-type mice yielded
a 750 bp band, while floxed mice were identified by the presence
of a 650 bp band. For detection of Cre-mediated excision of exon
19 of the Rb gene (hereafter designated Rb
D19), primers Rb18 and
Rb212 (59 GAA AGG AAA GTC AGG GAC ATT GGG 39)
were used, yielding a 260 bp product when recombination has
occurred and a 750 bp product for the unrecombined fraction.
Tissue Collection
Animals were euthanized by CO2 asphyxiation at 60, 120, 180,
or 240 days post-injection of AdGFP or AdCre. The ovaries (with
the ovarian fat pad and bursa intact) were removed individually
along with the attached oviduct and a portion of the uterus, fixed
in formalin and paraffin-embedded. Five mm serial sections were
cut for H&E staining and morphological changes to the OSE were
assessed by examining five non-consecutive sections of each ovary
at 2006 magnification using an Olympus BX50 microscope
(Olympus, Melville, NY, USA). Samples were blinded prior to
examination. Sections were evaluated for the number of areas of
columnar cells, areas of hyperplasia, and invaginations of the
OSE, as described previously [36]. Mice that developed tumors
were euthanized when they had reached a loss-of-wellness
endpoint due to tumor burden, defined as any or all of the
following: presence of respiratory distress, rapid weight loss or
gain .5 g from the average body weight of control mice of the
same age, and presence of a palpable mass or abdominal
distention that impairs mobility. Tumors were removed, fixed in
formalin and paraffin embedded, with a small piece of tissue
reserved for genomic DNA isolation. Serial sections of tumor tissue
with a thickness of 5 mm were cut for H&E staining and
immunohistochemistry.
Immunohistochemistry
Paraffin sections were deparaffinized in xylene and rehydrated
in ethanol according to standard protocol. High temperature
antigen retrieval was performed using sodium citrate buffer
(pH 6.0) and endogenous peroxidase activity was blocked using
3% hydrogen peroxide in Stockholm PBS (S-PBS). All samples
were blocked using an avidin/biotin blocking kit (DAKO,
Cytomation, Carpentaria, CA, USA). Primary antibodies were
diluted in S-PBS at the following concentrations: rat anti-CK19,
1:100 (TROMA-1, Developmental Studies Hybridoma Bank,
University of Iowa, USA); rat anti-Ki67, 1:25 (DAKO); mouse-
anti smooth muscle actin (SMA), 1:100 (DAKO); mouse anti-
Desmin, 1:100 (DAKO); and rat anti-CD34, 1:50 (Novus
Biologicals). For antibodies raised in rat, sections were incubated
with primary antibody at room temperature for 2 hours or
overnight. Following three 5 min washes in S-PBS, sections were
stained with an anti-rabbit secondary antibody (1:200, DAKO) for
20 min followed by three 5 min washes and incubation with a
streptavidin/horseradish peroxidase solution (1:200, DAKO) for
20 min. For antibodies raised in mice, the VectorH Mouse on
Mouse
TM immunodetection kit (Vector Laboratories, Burlingame,
CA, USA) was used according to manufacturer specifications.
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substrate (0.2% DAB, 0.001% H2O2; Sigma-Aldrich). Slides were
counterstained with hematoxylin, dehydrated, and coverslipped
with Permount mounting medium (Fisher Scientific, Ottawa, ON,
Canada).
MOSE Proliferation and Sensitivity to Cisplatin
Primary cultures of MOSE cells were established and
maintained as previously described [36]. For in vitro infections,
5.0610
5 MOSE cells of the various genotypes were infected with
either AdCre or AdGFP following an established protocol [35],
and experiments to evaluate proliferation and cisplatin sensitivity
were performed following cell replating 72 hours later, as
described previously [36]. Proliferation of MOSE cells was also
assessed several passages (4–9) after infection. Experiments were
performed three times in triplicate, with a separate infection for
each replicate.
Statistical Analyses
Cell counts are expressed as the mean6SEM of three
independent experiments performed in triplicate. The probability
of significant differences was determined by Student’s t test (two
groups) and by analysis of variance (ANOVA; multiple groups).
Bonferroni’s post-test was used to determine significance between
specific treatments when whole group differences were detected by
ANOVA. Survival curves were compared using a Log-Rank test.
For all analyses, significance was inferred at P,0.05 and P values
were two-sided. Analyses were performed using Graphpad Prism
statistical software (Graphpad Software, San Diego, CA, USA).
Results
Conditional Inactivation of Brca1 in Conjunction with p53
and/or Rb Using Intrabursal Injection
We have previously shown that inactivation of Brca1 alone in
the OSE resulted in an increase in the number of preneoplastic
changes in the OSE after 240 days, but no tumor formation [36].
In this study we observed that no tumors arose in mice in which Rb
alone was conditionally inactivated, even after one year following
intrabursal injection of AdCre. There were no significant
differences in the number of morphological changes in the OSE
between the AdCre-treated Rb
D19 mice and the control Rb
loxP/loxP
mice at any of the time points examined (Table 1). There was no
significant age-related increase in the total number of changes, as
was previously observed in the Brca1
D5-13 mice. However, the
mean number of morphological changes in the OSE doubled
between 120 and 180 days in the Rb
D19 mice (4.3260.78 versus
8.5260.80 mean changes per section over five non-consecutive
sections per ovary, P,0.05), whereas this difference was not noted
in the Rb
loxP/loxP mice.
Tumor formation was also not observed in mice in which both
Rb and Brca1 were concomitantly inactivated via intrabursal
injection of AdCre. The number of morphological changes in the
OSE increased over time in both groups, however there were no
significant differences between the Rb
D19/Brca1
D5-13 ovaries and
the Rb
loxP/loxP/Brca1
loxP/loxP ovaries at any time point examined
(Table 2). There was a significant increase in the number of areas
of columnar cells between 60 and 240 days in the Rb
D19/Brca1
D5-13
mice (1.9660.45 versus 5.1860.70, P,0.01) that was not seen in
the Rb
loxP/loxP/Brca1
loxP/loxP mice. As well, epithelial invaginations
were noted only in the OSE of the Rb
D19/Brca1
D5-13 mice.
Tumor formation was observed following intrabursal injection of
AdCre to generate cells with the following genotypes: p53
D2-10,
Rb
D19/p53
D2-10, Brca1
D5-13/p53
D2-10,a n dRb
D19/p53
D2-10/Brca1
D5-13
(Table 3).Notumorswereobservedinanyofthemiceinjectedwith
adenoviral GFP when followed to one year post-intrabursal
injection. The presentation of the mice at endpoint was similar in
all of the groups examined, with either a large, palpable dorsal
mass(es) or severe abdominal distention. The period between onset
of symptoms and loss-of-wellnessendpoint was quite short, generally
one week or less. Figure 1 illustrates the general appearance of the
tumors upon necropsy for each genotype. The tumors were most
often located at the end of the uterine horn involving the ovary and
sometimes engulfing surrounding organs such as the pancreas and
the spleen. Both ovaries were subjected to intrabursal injection in all
animals, however bilateral tumors were only observed in the Rb
D19/
p53
D2-10/Brca1
D5-13 mice, and only in 2 of 14 animals. The
incidence, median survival, range of survival and presence of ascites
Table 1. Distribution of morphological features in the OSE over time following conditional inactivation of Rb.
Time (Days)
Epithelial Morphology 60 120 180 240
Areas of Columnar Cells
Rb
D19 3.3460.33
a (n=10) 2.3860.49
a (n=10) 4.0060.53
a (n=10) 4.3360.67
a (n=8)
Rb
loxP/loxP 2.4860.28
a (n=10) 2.9960.53
a (n=8) 4.7660.53
b (n=10) 4.0260.36
a (n=10)
Areas of Hyperplasia
Rb
D19 2.6060.77
a 1.9060.54
a 4.5260.67
a 2.0860.38
a
Rb
loxP/loxP 2.4360.69
a 2.9660.93
a 3.0460.70
a 2.3260.50
a
Epithelial Invaginations
Rb
D19 0.1360.07
a 0.0460.04
a 0
a 0.0660.06
a
Rb
loxP/loxP 0
a 0.0360.03
a 0
a 0
a
Total Changes
RbD
19 6.0560.86
a 4.3260.78
a 8.5260.80
b 6.4060.80
a
Rb
loxP/loxP 4.9060.79
a 5.9861.16
a 7.8061.10
a 6.4060.63
a
Numbers represent the mean6SEM number of morphological changes per section over five non-consecutive sections in n ovaries. Superscript letters denote a
significant difference between time points for that treatment group.
doi:10.1371/journal.pone.0008534.t001
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Kaplan-Meier survival plots depicted in Figure 2.W h e nc o m p i l e d ,
these data indicate that loss of p53 is necessary for tumor formation
and that Brca1 deficiency accelerates tumor initiation and/or
progression.
Recombination at the relevant loxP sites was confirmed in
genomic DNA from all the tumor samples (Figure 3). Un-
recombined DNA was also detectable in all tumor samples, which
was not unexpected given that the tumors are likely composed of
both tumor cells and the cells of the normal tissue they have
invaded. Recombination at the relevant loxP sites was also
detectable in genomic DNA from ascites cells isolated from tumor-
bearing mice (data not shown).
Histopathologic Features of Tumors in Mice with
Conditional Inactivation of Brca1, p53 and Rb
There was no obvious difference in the pathology of the tumors
as related to their genotype. H&E stained sections revealed
densely-packed and highly malignant cells with spindle-shape
morphology, as well as the presence of anaplastic giant cells in all
of the samples examined (Figure 4A). Further immunohisto-
chemical analyses revealed that the tumors were predominantly
negative for the epithelial marker cytokeratin (CK) 19, with the
exception of some glandular structures present in a small number
of the tumors (Figure 4B). These tumors were also probed for the
presence of other epithelial markers such as CK8 and pan-
cytokeratin and were found to be negative with the exception of
the areas noted above. All of the tumors examined were positive
for smooth muscle actin (SMA) (Figure 4C) and desmin
(Figure 4D), both smooth muscle markers, and were negative
for CD34, a hematological marker (Figure 4E). Pathologic review
of tumor histology and immunohistochemical data indicates that
these tumors are malignant leiomyosarcomas.
The gross pathology along with the H&E sections provided
some clues as to the origin of the tumors. In some instances,
normal ovary was visible at the edge of a tumor, such that the
bursal membrane that surrounds the ovary was flush with the
tumor (Figure 5A). In some cases, even when normal ovary was
not grossly visible at necropsy, the ovary was found within the
H&E sections of the tumor (Figure 5B). In these sections, the
tumors also appeared to be connected to the bursal membrane
(Figure 5C). Staining of sections of normal ovaries revealed that
the bursa, which is an extension of the oviduct, is highly positive
for SMA (Figure 5D). Staining also revealed that the inner lining
Table 2. Distribution of morphological features in the OSE over time following conditional inactivation of Rb and Brca1.
Time (Days)
Epithelial Morphology 60 120 180 240
Areas of Columnar Cells
Rb
D19/Brca1
D5-13 1.9660.45
a (n=10) 4.0060.59
a (n=10) 4.2760.49
a (n=12) 5.1860.70
b (n=10)
Rb
loxP/loxP/Brca1
loxP/loxP 3.2460.43
a (n=10) 3.3860.31
a (n=10) 3.3060.32
a (n=12) 5.0260.85
a (n=10)
Areas of Hyperplasia
Rb
D19/Brca1
D5-13 2.6460.68
a 2.7060.84
a 4.2360.75
a 4.1460.84
a
Rb
loxP/loxP/Brca1
loxP/loxP 1.7660.40
a 2.8060.62
a 3.0860.68
a 2.4260.87
a
Epithelial Invaginations
Rb
D19/Brca1
D5-13 0 0 0.3560.25 0.2060.11
Rb
loxP/loxP/Brca1
loxP/loxP 00 0 0
Total Changes
Rb
D19/Brca1
D5-13 4.6261.08
a 8.8561.06
a 8.5260.80
a 9.5261.51
a
Rb
loxP/loxP/Brca1
loxP/loxP 5.0060.72
a 6.3860.90
a 7.8061.10
a 7.4461.62
a
Numbers represent the mean6SEM of the number of morphological changes per section over five non-consecutive sections in n ovaries. Letters are used to denote a
significant difference between time points for that treatment group.
doi:10.1371/journal.pone.0008534.t002
Table 3. Tumor formation following intrabursal injection of adenoviral Cre recombinase.
Genotype # of mice
a # of mice with tumors Median survival in days (range) % with ascites
Brca1
D5-13 50
Rb
D196 50
Rb
D19/Brca1
D5-13 50
p53
D2-10 8 8 179.5 (101–200) 50
Rb
D19/p53
D2-10 10 10 170 (99–207) 30
Brca1
D5-13/p53
D2-10 12 12 147.5 (105–166) 42
Rb
D19/p53
D2-10/Brca1
D5-13 14 14 118.5 (89–183) 0
aNumber of mice indicates the number of animals who received intrabursal injection of adenoviral Cre recombinase and were euthanized when they had reached a loss-
of-wellness endpoint due to tumor burden or had reached the 240 day time point.
doi:10.1371/journal.pone.0008534.t003
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Representative images of tumors arising in mice in which Brca1, p53, and/or Rb had been inactivated in the OSE: p53
D2-10 (A), Brca1
D5-13/p53
D2-10 (B),
Rb
D19/p53
D2-10 (C), and Rb
D19/p53
D2-10/Brca1
D5-13 (D).
doi:10.1371/journal.pone.0008534.g001
Figure 2. Survival of mice following inactivation of multiple tumor suppressors in the OSE in vivo. Kaplan-Meier plots showing the time to
loss-of-wellness endpoint of the mice in which Brca1, p53,a n d / o rRb had been inactivated in the OSE. A) The median survival time of the Brca1
D5-13/
p53
D2-10 mice (147.5 days) is significantly shorter than that of the p53
D2-10 mice (179.5 days), P,0.05. B) The median survival time of the Brca1
D5-13/
p53
D2-10 mice (147.5days)is significantlylessthanthatofthe Rb
D19/p53
D2-10 mice (170days),P,0.001.C) The mediansurvivaltimeofthe Rb
D19/p53
D2-10/
Brca1
D5-13mice(118.5days)issignificantlylessthanthatoftheRb
D19/p53
D2-10mice(170days),P,0.05.D)ThemediansurvivaltimeoftheRb
D19/p53
D2-10/
Brca1
D5-13 mice (118.5 days) is less than that of the Brca1
D5-13/p53
D2-10 mice (147.5 days), although the difference in survival was not statistically
significant.
doi:10.1371/journal.pone.0008534.g002
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from the p53
D2-10, Rb
D19/p53
D2-10, Brca1
D5-13/p53
D2-10, and
Rb
D19/Brca1
D5-13/p53
D2-10 mice at early time points (60 and 120
days) were uninformative in terms of potential precursor lesions for
these tumors. There were no advanced morphological changes
(invaginations or inclusion cysts) noted in ovaries collected from
the mice at 60 or 120 days post-AdCre injection (data not shown).
Effect of Concomitant Inactivation of Multiple Tumor
Suppressor Genes on Proliferation of MOSE Cells In Vitro
The appearance of non-epithelial tumors in the mice limited the
investigation of the consequences of disruption of the tumor
suppressor genes in OSE cells in vivo. We therefore isolated MOSE
cells from mice with conditional expression of these genes and have
previously demonstrated that inactivation of Brca1 in MOSE cells
resulted in decreased proliferation [36]. Inactivation of p53 in
p53
loxP/loxP MOSE cells had no effect on proliferation, but
proliferation was dramatically increased when both Brca1 and p53
were inactivated [36]. Here we show that, when growth rates were
examined 72 hours after exposure to AdGFP or AdCre, conditional
inactivation of Rb in Rb
loxP/loxP MOSE cells had no effect on
proliferation over the subsequent 96 hour period (Figure 6A). When
both Brca1 and Rb were inactivated in Rb
loxP/loxP/Brca1
loxP/loxP
MOSE cells, the proliferation defect seen when Brca1 was inactivated
alone (Figure 6G) was eliminated; however there was no significant
increase in the rate of proliferation of the Rb/Brca1-deficient cells
Figure 3. Recombination at loxP sites in the relevant tumor
suppressor genes in tumor samples. PCR of genomic DNA
extracted from the tumor and the corresponding tail (control for lack
of recombination) to detect recombination at loxP sites of the tumor
suppressor genes relevant to the genotype of the mouse.
doi:10.1371/journal.pone.0008534.g003
Figure 4. Representative images of tumor histology. Paraffin
sections (5 mm) of the tumors were stained with H&E or specific
antibodies to examine histology and gene expression: A) H&E (200X) B)
cytokeratin19 (400X) C) smooth muscle actin (200X) D) desmin (100X)
E) CD34 (100X). Antigen detection in B–E is by the presence of a
brownish-red stain.
doi:10.1371/journal.pone.0008534.g004
Figure 5. Tumors appear to be associated with the ovarian
bursal membrane. Gross anatomical image (A) and H&E sections (B
and C) showing involvement of ovarian bursal membrane with tumor.
T=tumor, b=bursal membrane, Ov=oviduct, O=ovary, and u=uterus
(25X). D) SMA staining (reddish-brown stain) of a normal ovary with an
intact bursal membrane (25X) E) CK19 staining (reddish-brown stain) of
a normal ovary with an intact bursal membrane (400X).
doi:10.1371/journal.pone.0008534.g005
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PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8534Figure 6. MOSE cell proliferation following inactivation of tumor suppressors. Number of viable MOSE cells evaluated 72 hours (A–D, G) or
several passages (E–F, H) after infection with AdCre or AdGFP. A) Rb
loxP/loxP MOSE cells evaluated 72 hours following infection with AdCre (Rb
D19) to
inactivate Rb or with AdGFP (Rb
loxP/loxP). B) Rb
loxP/loxP/Brca1
loxP/loxP MOSE cells infected with AdCre (Rb
D19/Brca1
D5-13) to inactivate Rb and Brca1 or with
AdGFP (Rb
loxP/loxP/Brca1
loxP/loxP). C) Rb
loxP/loxP/p53
loxP/loxP MOSE infected with AdCre (Rb
D19/p53
D2-10) to inactivate Rb and p53 or AdGFP (Rb
loxP/loxP/
p53
loxP/loxP). D) Rb
loxP/loxP/p53
loxP/loxP/Brca1
loxP/loxP MOSE infected with AdCre (Rb
D19/p53
D2-10/Brca1
D5-13) or AdGFP (Rb
loxP/loxP/p53
loxP/loxP/Brca1
loxP/loxP).
E–F, H) Proliferation of MOSE cells4–9 passages following infectionof AdCre or AdGFP. E) p53
loxP/loxP vs. p53
D2-10 MOSE. F) Rb
loxP/loxP vs.Rb
D19 MOSE. G)
Brca1
loxP/loxP vs. Brca1
D5-13 MOSE evaluated 72 hours following infection with AdCre or AdGFP. H) Brca1
loxP/loxP vs. Brca1
D5-13 MOSE, 4–9 passages
following infection with AdCre or AdGFP. I) PCR of genomic DNA collected from cultured Brca1
loxP/loxP OSE cells 1 or 6 passages following in vitro
infection with AdCre (Brca1
D5-13) or AdGFP (Brca1
loxP/loxP). Error bars represent the SEM of data obtained from three experiments performed in triplicate.
*, ** and *** indicate a significant difference where P,0.05, P,0.01 and P,0.001, respectively.
doi:10.1371/journal.pone.0008534.g006
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Rb
loxP/loxP/p53
loxP/loxP MOSE cells, the resulting Rb/p53-deficient
cells showed a dramatic increase in proliferation as compared to their
control (AdGFP-infected) counterparts, resulting in double the
number of cells counted after 72 and 96 hours (P,0.001;
Figure 6C). When all three tumor suppressor genes were inactivated
in the Rb
loxP/loxP/p53
loxP/loxP/Brca1
loxP/loxP MOSE cells, there was a
significant increase in their proliferation compared to the AdGFP-
infected cells (P,0.001; Figure 6D), resulting in a 2.7-fold increase
in cell number after 96 hours.
When the proliferation rate of p53
D2-10 MOSE cells was
examined several passages following AdCre infection, the p53-
deficient MOSE had developed a significantly increased rate of
proliferation compared to AdGFP-infected cells cultured for the
same length of time (P,0.001, Figure 6E). After several passages,
the Rb
D19 MOSE cells also had a significantly increased rate of
proliferation, detectable as early as 48 hours (Figure 6F). In
contrast, Brca1-deficient MOSE, which showed a reduced rate of
proliferation immediately after inactivation of Brca1 (Figure 6G),
failed to show any difference from their AdGFP-infected counter-
parts after several passages (Figure 6H). While recombination at
the loxP sites could still be detected in the AdCre-infected cells at
this stage, non-recombined DNA was now predominant
(Figure 6I), suggesting that the MOSE cells without recombination
were outgrowing the slower growing Brca1-deficient cells.
Effect of Inactivation of Multiple Tumor Suppressor
Genes on Sensitivity to Cisplatin in MOSE Cells In Vitro
Inactivation of Brca1 or p53 alone in MOSE cells in vitro renders
them significantly more sensitive to treatment with the chemo-
therapeutic agent cisplatin; however, when both Brca1 and p53 are
conditionally inactivated, there is no significant difference
between the sensitivities of Brca1
D5-13/p53
D2-10 and Brca1
loxP/loxP/
p53
loxP/loxP cells after 48 hours [36]. Here we show that the Rb
D19
MOSE cells were also significantly more sensitive to cisplatin
treatment than the Rb
loxP/loxP cells (33.28%60.95% versus
46.85%62.42%, P,0.01, viable cells expressed as a percentage
of untreated cells, Figure 7A). However, when both Rb and Brca1
or both Rb and p53 were inactivated in MOSE cells, there was no
difference in the proportion of cells remaining viable after
48 hours of treatment with cisplatin, relative to the AdGFP-
infected controls (Figure 7B,C). The concomitant inactivation of
all three tumor suppressor genes in the Rb
loxP/loxP/p53
loxP/loxP/
Brca1
loxP/loxP cells had no impact on the sensitivity of these cells to
treatment with 5 mM of cisplatin for 48 hours compared to the
corresponding control-infected cells (Figure 7D).
Discussion
Our previous work showed that when Brca1 was inactivated in
vivo via intrabursal injection of AdCre, no tumorigenesis occurred
when the animals were followed past one year post-injection,
despite the development of significantly more premalignant
changes in the OSE of these ovaries [36]. The frequent occurrence
of p53 mutations in ovarian cancers in women with BRCA1
mutations [25,26] and the apparent cooperation of Brca1 and p53
in mouse models of mammary cancers [27–31] led us to perform
experiments in which conditional inactivation of Brca1 was
targeted to the OSE, along with the conditional inactivation the
tumor suppressors p53 and/or Rb. Our results show that invasive
tumors developed in all mice that had inactivation of p53 targeted
to the OSE and that tumor development was accelerated in mice
with concomitant inactivation of Brca1.
Figure 7. Treatment of MOSE cells with cisplatin following inactivation of multiple tumor suppressors. MOSE cells with specific
inactivation of Brca1, p53, and/or Rb in various combinations were tested for their sensitivity to cisplatin by treatment with 5 mM cisplatin for 48 hours.
A) Rb
loxP/loxP MOSE cells infected with either AdCre (Rb
D19) or AdGFP (Rb
loxP/loxP); B) Rb
loxP/loxP/Brca1
loxP/loxP MOSE cells infected with either AdCre
(Rb
D19/Brca1
D5-13)orAd GF P(Rb
loxP/loxP/Brca1
loxP/loxP);C)Rb
loxP/loxP/p53
loxP/loxPMOSEcellsinfectedwitheitherAdCre(Rb
D19/p53
D2-10)orAd GF P( Rb
loxP/loxP/
p53
loxP/loxP); and D) Rb
loxP/loxP/p53
loxP/loxP/Brca1
loxP/loxP MOSE cells infected with either AdCre (Rb
D19/p53
D2-10/Brca1
D5-13)o rA d G F P( Rb
loxP/loxP/p53
loxP/loxP/
Brca1
loxP/loxP). Valuesare thenumberofadherent cells presentedas aproportion ofsimilarcells exposed tothe vehicle control (untreatedcells). Error bars
represent the SEM of three experiments performed in triplicate. **indicates a significant difference where P,0.01.
doi:10.1371/journal.pone.0008534.g007
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that the Rb
D19/p53
D2-10 mice would develop adenocarcinomas with
little to no tumor formation seen when either p53 or Rb was
inactivated alone. In contrast to that study, the Rb
D19/p53
D2-10 mice
in this study died of tumors that were classified as malignant
leiomyosarcomas. Furthermore, conditional inactivation of p53
alone led to the development of leiomyosarcomas in 100% of the
mice. Ovarian sarcomas are rare in women [40], although
aberrations in both the p53 and Rb pathways have been implicated
in the development and progression of leiomyosarcomas [41–43],
and mice that are null or heterozygous for p53 are highly prone to
developing lymphomas and sarcomas [44,45]. Several groups have
shown the capacity for OSE to develop into epithelial tumors using
the method of intrabursal injection of AdCre for the activation or
inactivation of genes [35,36,46], indicating that these cells are
capable of transformation to epithelial cancers. The reasons for the
prevalence of leiomyosarcomas are therefore unclear, but there are
several possible factors that should be considered. First, the OSE is a
poorly differentiated epithelium that is known to undergo epithelial-
mesenchymal transition during the peri-ovulatory period [1], and it
ispossiblethattheinactivationofp53facilitatedtransformationmore
effectively in these mesenchymal cells. Second, although evidence
from our lab and others [35,36,46] indicate that intrabursal delivery
of adenoviruses results in infection of primarily surface epithelial
cells, it may be possible that some underlying stromal cells are also
infected and are more readily transformed than the epithelial cells.
A third reason for the occurrence of leiomyosarcomas in this
study may be differences in the strain of mouse used. Genetic
modifiers due to strain differences can influence the phenotype in
mouse models of disease [47–49], so it is possible that strain
differences may account for the discrepancies in both tumor
incidence and histology. The animals utilized in the Flesken-
Nikitin study [35] were backcrossed to the FVB/n strain, whereas
the animals in this study were maintained on the FVB/n;129sv
mixed strain background. Finally, it is possible that, in the strain
used in this study, the smooth muscle cells of the bursal
membrane, which would also be in contact with the adenoviral
Cre recombinase, are more sensitive to the consequences of these
recombination events than the OSE. The bursal membrane is
largely composed of smooth muscle cells, much like the uterine
and oviductal myometrium with which it is contiguous. Since the
tumors that developed in these mice were generally found to be
continuous with the bursal membrane, it may be that the tumors
are arising from this tissue rather than the ovarian surface
epithelium. We have recently found that Cre-mediated recombi-
nation can occur in cells in the bursal membrane and that cells
carrying the recombined gene can still be found at least 65 days
after intrabursal delivery of AdCre [50].
Despite this unanticipated phenotype, Brca1-deficiency in these
tumors influenced the survival time of the mice, causing a
significant reduction in the length of survival of p53 and p53/pRb-
deficient mice, compared to the mice without Brca1 deficiency.
Breast and ovarian cancers in women with BRCA1 mutations arise
at an earlier age than sporadic cancers [51], so it was interesting to
observe that, despite the difference in histologic phenotype,
inactivation of Brca1 in mice resulted in tumors that developed
more quickly. This action is in agreement with a recent report
describing the ability of BRCA1 deficiency to accelerate uterine
leiomyosarcoma development [52]. The mechanism of this
acceleration in tumor initiation and/or progression is unknown,
although loss of Brca1 function is associated with genomic
instability [19].
When MOSE cell proliferation was examined in vitro, the
concomitant inactivation of p53 rescued the growth suppression
that was seen with inactivation of Brca1 alone [36] and led to a
substantially increased growth rate as compared to control cells.
Loss of p53 function has been demonstrated to partially rescue the
embryonic lethality of Brca1 knockout mice and appears to play a
critical role in mammary tumorigenesis in mice [27–31,53].
Concomitant inactivation of both p53 and Rb also resulted in a
significant increase in proliferation in MOSE cells, an observation
in agreement with results of similar studies reported previously
[35]. Conditional inactivation of all three tumor suppressor genes,
Brca1, p53 and Rb, simultaneously in MOSE cells resulted in a
dramatic increase in proliferation with significant increases in cell
number with time over any of the other genotypic combinations.
This increased rate of proliferation may explain the acceleration in
tumor progression in cells lacking all three genes.
Inactivation of p53 or Rb alone in MOSE cells had no
immediate effect on proliferation, but after at least four passages,
the growth characteristics became notably different, showing
increased rates of proliferation relative to controls. These results
suggest that, with prolonged culture, these cells may spontaneously
acquire further genetic abnormalities that result in uncontrolled
proliferation. The lack of any obvious morphological alterations in
the OSE at 60 or 120 days after intrabursal AdCre injection in
p53/Rb-deficient mice supports the hypothesis that tumor
initiation requires additional genetic changes. The long latency
in tumor development could be a result of the relatively low
proliferative index of the OSE [54].
The increased sensitivity of MOSE to cisplatin treatment
observed when only one tumor suppressor gene is inactivated
appears to be lost when two or more are inactivated simulta-
neously. Cisplatin-resistant ovarian and cervical carcinoma cells
have been shown to harbour multiple genetic changes, particularly
affecting pathways leading to apoptosis that render the cells
aberrantly tolerant of accumulated DNA damage [55,56]. In this
regard, familial ovarian cancers have a higher frequency of p53
mutations than sporadic cancers [14], and it has been suggested
that loss of p53 function is required for a cell to tolerate the loss of
the Brca1 function [57–59]. Thus, loss of Brca1 may result in
compensation in the cell by the p53 or Rb pathways, resulting in an
increased apoptotic response to cisplatin. The concomitant loss of
the p53 or Rb expression may enable the cells to better tolerate
cellular stresses, including exposure to cisplatin.
These results show similarities to mouse models of mammary
tumorigenesis and uterine leiomyosarcomas in that Brca1 inacti-
vation can accelerate the initiation and/or progression of p53-
mediated tumors. Brca1 status, in combination with that of other
tumor suppressor pathways, influence sensitivity of OSE cells to
chemotherapeutic agents. The combination of tumor suppressors
inactivated in this study failed to yield epithelial cancers, indicating
that further analyses are needed to determine the mechanisms by
which BRCA1 mutations cause transformation of the ovarian
epithelium.
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